A novel intrauterine contraceptive drug delivery system derived from the conventional GyneFix® intrauterine implant system is described and the preliminary results in 22 women are discussed. The first objective of the development of the GyneFix-levonorgestrel system was to reduce menstrual bleeding, whether or not related to the effect of copper, by combining a shortened version of the standard GyneFix implant, having a copper surface area of 200 mm2, with a system for the sustained intrauterine delivery of levonorgestrel. The results of this initial observational study indicate that the GyneFix-levonorgestrel system, apart from being well tolerated, is safe and effective. The levonorgestrel component appears to have a beneficial effect on the amount of bleeding. A study on menstrual blood loss will be carried out to substantiate this assumption.
|Number of pages||5|
|Journal||European Journal of Contraception and Reproductive Health Care|
|Publication status||Published - 1999|
- Intrauterine device
- Menstrual bleeding
- Sexually transmitted infections